Breaking News
July 17, 2018 - Long-term survival worse for black survivors of in-hospital cardiac arrest
July 17, 2018 - Stanford data analyst’s childhood inspires his research: A Q&A
July 17, 2018 - Preventability of hospital readmissions changes over time, study reveals
July 17, 2018 - Nursing notes can help predict if ICU patients will survive
July 17, 2018 - Okayama University research could improve prognosis of diabetic kidney disease
July 17, 2018 - Study identifies new genes linked to heart function and development
July 17, 2018 - NeuroTrauma Sciences and Henry Ford join hands to advance exosome technology
July 17, 2018 - Improved methods to measure enterococci concentrations in recreational water
July 17, 2018 - White adolescent boys experiencing early puberty have high risk for substance use
July 17, 2018 - Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia
July 17, 2018 - Roots of leukemia reveal possibility of predicting people at risk
July 17, 2018 - Summer med program embraces low-income students’ potential
July 17, 2018 - New research lays foundation to create standards for RNA sequencing
July 17, 2018 - CRISPR/Cas9 gene editing can cause greater genetic damage than previously thought
July 17, 2018 - Democrats rally against threats to the ACA to block Trump’s Supreme Court nominee
July 17, 2018 - Staggering prices slow insurers’ coverage of CAR-T cancer therapy
July 17, 2018 - How proteins involved in neurodegeneration enter cells
July 17, 2018 - New super-resolution ‘nanoscope’ provides insight into progression of Alzheimer’s disease
July 17, 2018 - FDA Advisory Committee Endorses the Effectiveness and Safety of Single-Dose Tafenoquine for the Radical Cure of P. vivax Malaria
July 17, 2018 - Uncovering the evolutionary history of IBD-associated colorectal cancer
July 17, 2018 - Is nutrition research dependable? Stanford’s John Ioannidis weighs in
July 17, 2018 - New machine learning framework predicts effects of genetic mutations in ‘dark matter’ regions
July 17, 2018 - Plant-based products fail to have positive impact on blood pressure during clinical studies
July 17, 2018 - Electronic system to speed up facial pain diagnosis may improve quality of life and save money
July 17, 2018 - Study delves into the role played by Protein Kinase C in synaptic plasticity
July 17, 2018 - Women Often Unaware of Their Hospital’s Religious Affiliation
July 17, 2018 - New AASM guideline recommends use of actigraphy for sleep disorders
July 17, 2018 - CRISPR editing reduces repetitive behavior in mice with a form of autism
July 17, 2018 - Scientists use magnets to detect cancer
July 17, 2018 - Microfluidic chip to detect sepsis proves successful in clinical study
July 17, 2018 - Research provides better understanding of mechanisms underlying memory storage
July 17, 2018 - A Multi-Modal Approach for the Early Detection of Breast Cancer
July 17, 2018 - Mailing colorectal cancer tests to patients increases screening rates, report researchers
July 17, 2018 - Scientists find possible sources of medicinal and antimicrobial drugs
July 17, 2018 - Molecules formed when the body metabolizes omega-3 fatty acids may inhibit cancer
July 17, 2018 - Efficient communication between hospitals improves patient safety and reduces mortality
July 17, 2018 - Study highlights potential of fetal gene therapy to prevent lethal neurodegenerative disease
July 17, 2018 - For Americans, in Science They Trust
July 17, 2018 - Combating HIV/AIDS | NIH MedlinePlus the Magazine
July 17, 2018 - Study shows minorities widely underrepresented in autism diagnoses
July 17, 2018 - Multigene testing replacing BRCA tests for breast cancer risk | News Center
July 17, 2018 - Pre-clinical pilot study shows promising results of ‘concussion pill’
July 17, 2018 - Researchers reduce size of tumors in mice by artificially activating the brain’s reward system
July 17, 2018 - New study documents symptoms of people before they acquire multiple sclerosis
July 17, 2018 - Researchers discover why CRISPR gene editing sometimes fails
July 17, 2018 - New finding may hold key to better understand the complexities of neurological disorders
July 17, 2018 - The Current issue of “The view from here” is concerned with Novel Targets.
July 17, 2018 - Fighting the Flu with a Universal Vaccine
July 17, 2018 - Key social reward circuit in the brain impaired in kids with autism | News Center
July 17, 2018 - Insight into causes, types and treatment of aphasia
July 16, 2018 - Quark Pharmaceuticals, Inc Announces First Patient Dosed in Phase 3 Clinical Trial of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery
July 16, 2018 - NSAIDs shown to have causal role in cardiovascular risk of patients with osteoarthritis
July 16, 2018 - PET scan tracer predicts success of cancer ‘vaccine’ | News Center
July 16, 2018 - Parents struggle with what to do when their child has headache, shows study
July 16, 2018 - Outrageous or overblown? HHS announces another round of ACA navigator funding cuts
July 16, 2018 - Weight loss surgery may impact individual’s risk of developing cancer, shows study
July 16, 2018 - Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the U.S.
July 16, 2018 - Restoring epigenetic balance reinstates memory in flies with Alzheimer’s disease symptoms
July 16, 2018 - Magnetized wire could be used to detect cancer in people | News Center
July 16, 2018 - Non-surgical management found to be feasible option for penetrating kidney trauma
July 16, 2018 - California clinic screens asylum seekers for honesty
July 16, 2018 - FDA Approves Xtandi (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
July 16, 2018 - Can nanotechnology help treat Alzheimer’s?
July 16, 2018 - Researchers identify protein essential for making stem cells | News Center
July 16, 2018 - Severe childhood infections linked with lower school achievement in adolescence
July 16, 2018 - Radiologist discusses causes, treatments of varicose veins
July 16, 2018 - Researchers develop nanostructured surface to accelerate wound healing after dental implants
July 16, 2018 - New non-invasive procedure to reposition kidney stones could benefit astronauts
July 16, 2018 - Attending Surgeon Influences Genetic Testing in Breast Cancer
July 16, 2018 - Medical doctors with addictions fear professional repercussions if they seek treatment
July 16, 2018 - 5 Questions: John Ioannidis calls for more rigorous nutrition research | News Center
July 16, 2018 - University of Illinois buys 3D-Bioplotter for regenerative biology, tissue engineering research
July 16, 2018 - Charité’s researchers integrate open-source platform into the ‘Human Brain Project’
July 16, 2018 - SUSU scientists develop rehabilitation device for people with lower limbs injuries
July 16, 2018 - Researchers find definite increase in scooter-related injuries
July 16, 2018 - Researchers solve mystery of final blood group system
July 16, 2018 - Researchers develop near-infrared fluorophores-based PDT to cure cancer with less side effects
July 16, 2018 - Traumatic brain injury biomarker could help predict patient prognosis
July 16, 2018 - Researchers to investigate role of hormones in mosquito’s ability to use human blood for egg production
July 16, 2018 - AHA: Doctor Makes Lifesaving House Call in His Own Home
Cancer researchers hit a bullseye with new drug target for Ewing sarcoma

Cancer researchers hit a bullseye with new drug target for Ewing sarcoma

image_pdfDownload PDFimage_print
Cancer researchers hit a bullseye with new drug target for Ewing sarcoma
Fluorescent staining shows how PARP and CDK12 inhibitors combine to deal a lethal blow to Ewing sarcoma. In the top row, green represents locations of DNA damage incurred by Ewing sarcoma cells. In the bottom row, red represents DNA repair activity. Together, PARP and CDK12 inhibitors lead to Ewing sarcoma cell death. Credit: Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

Screening a class of recently-developed drug compounds—so-called “CDK inhibitors” capable of blocking CDK7/12/13 proteins—against hundreds of different human cancer cell lines, researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center have found that CDK12 inhibitors pack a particularly lethal punch to Ewing sarcoma, a rare cancer typically affecting children and young adults.

“No one has previously considered CDK12 inhibition as a way to combat Ewing sarcoma,” says Kimberly Stegmaier, MD, senior author of the new Cancer Cell paper that describes the findings.

In 2014, Nathaneal Gray, PhD, co-author on the new paper, and his team were the first to develop CDK inhibitors.

“Now, in mice, we’ve shown that Ewing sarcoma cells die if CDK12 is knocked out genetically or chemically inhibited,” Stegmaier says. What’s more, her team has discovered that CDK12 inhibition can be combined with another drug, called a PARP inhibitor, to double down on Ewing sarcoma cells.

The revelation that CDK12 inhibition can kill Ewing sarcoma cells brings a surge of hope to the field of pediatric oncology, which has long been challenged to find new drugs against childhood cancers.

“Pediatric cancers often involve abnormalities in genes that encode for transcription factors, shapeshifting proteins that bind to DNA sequences to activate or repress gene expression,” says Stegmaier, who co-directs the pediatric hematologic malignancy program at Dana-Farber/Boston Children’s and is a member of the Broad Institute’s Cancer Program. “Due to their disordered physical structure, transcription factors have largely eluded drug discovery efforts.”

A molecular view of Ewing sarcoma

In Ewing sarcoma, the second-most common bone cancer in children and adolescents, an error involving two genes gives rise to an abnormal fusion transcription factor called EWS/FLI. Once produced, EWS/FLI wreaks havoc by tripping the switch of normally quiet regions of DNA, turning on genes that are supposed to stay off, while also turning off genes that should be active.

Cancer researchers call EWS/FLI a “pioneer factor” for its ability to turn on genes that wouldn’t be expressed otherwise.

“In Ewing sarcoma and other cancers involving transcription factor fusion ‘onco-proteins’ like EWS/FLI, these mutated transcription factors drive abnormal cell behavior and tumor growth,” Stegmaier explains. “EWS/FLI has so far not been able to be targeted by conventional drug chemistry.”

Cancer researchers hit a bullseye with new drug target for Ewing sarcoma
Infographic showing how PARP and CDK12 inhibition lead to deficient DNA damage repair and cell death in Ewing sarcoma cells. Credit: Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

But now, Stegmaier and her team may have unleashed a workaround to disarming EWS/FLI-expressing tumor cells via CDK12, a readily-targetable enzyme. After their wide-ranging drug screen revealed a potential link between CDK12 inhibition and Ewing sarcoma, the team sought to understand why.

“CDK12 is known to be important for gene regulation, so we wondered why the EWS/FLI fusion protein might engender sensitivity to CDK12 inhibitors,” Stegmaier says.

Getting to the root of CDK12’s role

In a mouse model, the team showed that CDK12 inhibitors greatly slow down tumor growth and extend the survival rates of mice with Ewing sarcoma tumors.

Searching through the scientific literature, the team found that other cancer researchers had documented a link between CDK12 and ovarian cancer. Ovarian tumors with a genetic mutation inactivating the CDK12 protein are exquisitely sensitive to FDA-approved drugs called PARP inhibitors, which block the activity of PARP proteins involved in DNA damage repair and other cellular processes.

Stegmaier’s project team, led by postdoctoral fellow Amanda Balboni Iniguez, PhD, hypothesized that inhibiting CDK12 in Ewing sarcoma might have a double-whammy clinical benefit: slowing down the growth of Ewing cells and also making them lethally sensitive to PARP inhibitors.

A new drug cocktail for Ewing sarcoma?

“When we combined CDK12 and PARP inhibitors in Ewing sarcoma cells in culture dishes and in mouse models of Ewing sarcoma, we saw a very dramatic effect; some individuals were entirely cured of the disease,” Stegmaier says. “We have discovered that CDK12 inhibitors repress genes important to the regulation of DNA damage in Ewing sarcoma cells, and therefore these EWS/FLI positive Ewing sarcoma cells are very sensitive to PARP inhibitors.”

What’s more, the CDK12 and PARP inhibitor drug combination had no toxic effect on the bone marrow of the mice. In contrast, PARP inhibitors given in combination with chemotherapy have already shown to create a high amount of bone marrow toxicity in humans.

Given these experimental results, Stegmaier is excited about the future potential for testing the combination of CDK12 and PARP inhibitors in clinical trials.

“PARP inhibition is already FDA-approved for use in certain cancers, and inhibitors of CDK12 and other CDK proteins are in early-phase clinical testing,” Stegmaier says. “If they are proven to be safe in adults, I hope we can extend testing to children with Ewing sarcoma.”


Explore further:
A noncoding RNA promotes pediatric bone cancer

Journal reference:
Cancer Cell

Provided by:
Children’s Hospital Boston

Tagged with:

About author

Related Articles